TLDR: ZhiYuan ShenLan, a company founded in 2024 and incubated by MegaGenius Technology, has successfully closed an angel-round financing of tens of millions of yuan. The funding, led by Woyan Capital with participation from Tianfeng Capital, Inno Angel Fund, and Lingyi Venture Capital, will fuel the development of its generative AI platform for biomolecules and an autonomously driven molecular function evolution platform, alongside market expansion efforts. The company is at the forefront of leveraging AI to revolutionize biomolecular design and manufacturing.
Beijing-based ZhiYuan ShenLan, a pioneering company focused on data-driven biomolecule design and manufacturing, has announced the successful completion of its angel-round financing, securing tens of millions of yuan. The investment round was spearheaded by Woyan Capital, with significant contributions from Tianfeng Capital. Existing shareholders, Inno Angel Fund and Lingyi Venture Capital, also continued their participation in this crucial funding stage. The news was exclusively reported by 36Kr.
Established in 2024 and incubated by MegaGenius Technology, ZhiYuan ShenLan is poised to utilize these newly acquired funds to advance its core technological initiatives. The primary allocation of capital is designated for the construction of a cutting-edge generative AI platform specifically tailored for biomolecules. Additionally, a portion of the investment will be directed towards building an autonomously driven molecular function evolution platform and expanding its business market reach.
Dr. Wang Chengzhi, the founder of ZhiYuan ShenLan, brings over two decades of experience in the life sciences field, having previously served as the chief scientist at MegaGenius Technology. Dr. Wang emphasizes that generative AI (GenAI) is currently instigating a profound transformation within the life sciences sector. He notes that the traditional R&D paradigm, characterized by ‘large-scale trial and error,’ is rapidly transitioning towards a more efficient model of ‘precise design and creation’ through AI.
ZhiYuan ShenLan’s strategic vision is to evolve the field of AI for Science from its current 2.0 ‘navigation-style design engine’ phase to a more advanced 3.0 ‘scientific intelligent autonomous platform.’ This ambitious goal underscores the company’s commitment to pushing the boundaries of bioengineering and molecular design through innovative data-driven approaches.
Also Read:
- Generative AI Achieves Unprecedented Atomic Precision in De Novo Antibody Design, Revolutionizing Drug Discovery
- NIH Grant of $2 Million Accelerates AI-Powered Gene Editing for Disease Cures
While advancements like AlphaFold 2 have enabled the prediction of structures for hundreds of millions of proteins, the industry’s critical focus remains on the function of these proteins, rather than merely their intermediate structures. ZhiYuan ShenLan distinguishes itself by prioritizing ‘function’ as the central object of optimization, actively exploring functional requirements within real-world application scenarios. This functional-first approach aims to address a key industry need and drive meaningful progress in biomolecular innovation.
